Our Mission is to improve the lives of those affected by Central Nervous System (CNS) related disorders by developing better translatable solutions to accelerate and optimize CNS drug discovery.
NeuCyte is an early-stage biotechnology company solely focused on neurological diseases. With the expertise on advancing the drug discovery process by using cell based target identification and drug discovery platforms, NeuCyte puts an emphasis on the biology insight of the disorders to develop novel drugs that truly address the altered biological state of the patients.
Our technology accelerates the lead drug identification and optimization process. Our unique human neural platform allows for the evaluation of human specific neural phenotypes that are not identifiable in traditional animal models. This allows for a more reliable predictor of drug efficacy and potential neurotoxicity.
As a platform company, NeuCyte has a product and service devision, NeuCyte Laboratories. NeuCyte Labs offers iPSC-derived induced neural cells and drug discovery and nonclinical safety assessment services.
The NeuCyte staff and scientific advisory board are comprised of some of the top stem cell biologist and neuroscientist in the world. The vast knowledge from our team gives us an unrivaled advantage to address the unmet needs of patients with neurological disorders.
Scientific Advisory Board
Paul J. Hagerman, MD, PhD
Distinguished Professor in Biochemistry and Molecular Medicine, University of California at Davis
Pamela Lein, PhD
Department Chair and Professor, Molecular Biosciences, School of Veterinary Medicine, University of California at Davis
Zhiping P. Pang, MD, PhD
Associate Professor of Neuroscience and Cell Biology
Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School
Julia TCW, PhD
Assistant Professor of Pharmacology and Bioinformatics,
Director and Principal Investigator, Laboratory of Human Induced Pluripotent Stem Cell Therapeutics, Boston University
Edsel Abud, MD, PhD
KL2 Clinical Scholar at Scripps Translational Institute
His PhD work helped develop one of the first and most widely used methods to generate microglia cells from iPSCs, showing their functional genomics and role in health and disease.
Why Partner with NeuCyte?
NeuCyte has created a proprietary platform based on iPSC technology that enables translatable neuroscience. Solely focusing on neurological disorders, NeuCyte has put together a world-class scientific team of experts for extracting and understanding human disease related phenotypes for target identification.
By harnessing the power of the SynFire® neural cells, our platform allows for in vitro modeling of neurological disorders using disease relevant cells, as well as for phenotypic and target-based drug screens.
NeuCyte is open to exploring strategic partnerships to accelerate our current drug discovery programs and to expand the use of our platform beyond our internal R&D programs. We are interested in pursuing other neurological disease models, technologies and drug candidates that are consistent with our core mission of helping those suffering from neurological related illnesses.
For more information, please contact us at email@example.com